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Repetitive transcranial magnetic stimulation (rTMS) Dorsomedial prefrontal cortex (DMPFC) Major depressive disorder (MDD) a b s t r a c t Background: Dorsomedial prefrontal cortex (DMPFC) repetitive transcranial magnetic stimulation (rTMS) is a novel intervention for treatment-refractory depression (TRD). To date, many open-label case series and one randomized controlled trial of modest sample size have provided preliminary evidence that DMPFC-rTMS is an effective treatment for TRD. Here, we report the results of a large, doubleblinded, sham-controlled trial of DMPFC-rTMS for TRD.
Objective: The primary aim of this study was to determine the efficacy of DMPFC-rTMS for TRD under sham-controlled conditions.
Methods: 120 TRD patients were randomized to receive 30 twice-daily sessions of either active highfrequency, active low-frequency, or sham DMPFC-rTMS using a novel bent active/sham double-cone coil. Placebo stimulation also involved the use of surface electrodes placed above the eyebrows. The 17-item Hamilton Rating Scale for Depression served as the primary outcome measure.
Results: Although there was a significant main effect of treatment across all arms, active DMPFC-rTMS was not superior to sham. Both participants and assessors were unable to accuracy determine whether patients received active or placebo stimulation. However, technicians' treatment arm guesses were significantly above chance.
Conclusion: DMPFC rTMS did not result in improvement of depressive symptoms greater than sham stimulation. We cannot rule out that the sham apparatus may also have elicited an antidepressant effect via electrical trigeminal stimulation; future DMPFC-rTMS trials are therefore warranted.
© 2019 Elsevier Inc. All rights reserved.
To the Editor:
Treatment-resistant major depressive disorder (TRD) is associated with high rates of economic and personal burden [1] . Conventional rTMS for TRD employs left high-frequency or right lowfrequency dorsolateral prefrontal cortex (DLPFC), with response and remission rates between 50-55% and 30e35%, respectively, for the most recent generation of clinical trials [2] . One novel rTMS target for TRD is the dorsomedial prefrontal cortex (DMPFC) [3] . To date, a single double-blind sham-controlled trial of medial prefrontal rTMS for TRD has been published [4] . In that study, Kreuzer and colleagues reported a significant treatment groupby-time interaction on the primary clinical measure of their study, post hoc comparisons revealed that both active mPFC-rTMS and DLPFC-rTMS were not superior to sham rTMS. Despite this finding, open-label studies have found that roughly half of patients respond and one third of patients remit following DMPFC-rTMS; these rates are comparable to recent randomized controlled trials of DLPFC-rTMS [2, 3] .
To improve clinical outcomes, rTMS protocols that theoretically elicit different physiological responses to the same brain region could be compared both for clinical efficacy and for effects on neural activity; such comparisons could help to identify mechanisms of response and to optimize treatment parameters. Consequently, the aim of the current study is to determine the treatment efficacy of high-and low-frequency active DMPFC-rTMS versus sham stimulation. We hypothesized that active 20 Hz DMPFC-rTMS would be superior to that of sham rTMS and 1 Hz DMPFC-rTMS.
A complete description of the methods is found in the Supplemental Materials. To summarize, patients enrolled in the study met standardized criteria for MDD, failed to response to at least one course of antidepressant medication or psychotherapy within the current episode; and had a 17-item Hamilton Rating Scale for Depression (HRSD) score of at least 18 at the time of their screening visit. All participants provided informed consent, and the study was approved by the University Health Network Research Ethics Board (ClinicalTrials.gov Identifier: NCT02702154).
Eligible participants were randomized into one of two active treatment arms: 1 Hz DMPFC-rTMS or 20 Hz DMPFC-rTMS, or a sham rTMS arm. Before the first session of rTMS, the motor threshold for each participant was visually determined using previously published methods [5] . rTMS was delivered using the MagPro R30 stimulator and a specially designed Active/Sham DB80 (Mag-Venture, Farum, Denmark) coil for all rTMS treatments, with one double-cone coil in contact with the scalp for active treatment, and the opposite coil for sham stimulation. Surface electrodes connected to the stimulator were placed bilaterally above the eyebrows for all treatments.
The 17-item HRSD [6] served as primary clinical outcome measures for the study, as in previously reported trials of DMPFC-rTMS [3, 5] ; the HRSD was administered pre-treatment, weekly (every 5 treatment days) throughout treatment, immediately posttreatment, and at 1-, 4-, and 12-weeks post-treatment. We used a mixed-effects model in SPSS (IBM Corp., Armonk, NY) to assess whether clinical improvement over the course of the study differed between the treatment arms, covarying for any clinical or demographic differences between treatment groups. 120 of the 143 MDD participants screened met the study's eligibility requirements (78 female, mean age ¼ 39.44 ± 11.62), and 108 participants completed treatment (Table S1, Fig. S1 ). rTMS targeting the DMPFC was well-tolerated. A significant main effect of time was found (F(5,112) ¼ 27.60, p < 0.001), but there were no significant group-by-time interactions (F(10,113) ¼ 1.01, p ¼ 0.44) ( Fig. 1 ). Neither clinical assessors nor patients were able to correctly guess treatment allocations better than chance (Assessor:
However, technicians were able to determine who received active versus sham treatment significantly better than chance (c 2 ¼ 23.69, df ¼ 1, p < 0.001).
There are major methodological differences between the current study and previous trials of open-label and double-blind DMPFC-rTMS that warrant further study of this treatment for TRD. First, unlike the original trial [4] and many [3, 5] but not all [7, 8] of our previous open-label studies, the current study employed 30 twice-daily 20 Hz rTMS sessions instead of 20e30 once-daily 10 Hz sessions. If the twice-daily stimulation did not achieve a twofold acceleration of effect in most patients, then the overall course length of 15 days may have been inadequate. However, a recent study of once-daily 10 Hz versus twice-daily 20 Hz open-label DMPFC-rTMS showed similar rates of improvement and response rates [8] . We also recently reported comparable response rates in an open-label case series of 20 Hz DMPFC-rTMS [7] .
Another concern is whether the 'sham' stimulation electrodes, placed at regions above the eyebrows, might have inadvertently delivered therapeutic doses of transcranial electrical stimulation or trigeminal nerve (V1) stimulation. One sham-controlled trial [9] reported significant antidepressant effects of V1 stimulation. Although the V1 stimulatory parameters reported in these studies are unlike our sham stimulation, it is possible that these electrodes inadvertently induced an antidepressant effect in the sham arm via V1 stimulation. As sham design for TMS interventions is currently a major challenge in the field [10] , future studies should consider alternative sham designs.
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